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Abstract
 Objectives: The purpose of this study was to determine patient characteristics and other factors 
associated with discontinuation of complementary and alternative medicine (CAM) among cancer patients 
in Korea. Methods: A national, multicenter, cross-sectional survey of cancer patients was performed in 
which 674 of 2,661 patients were analyzed for their use of CAM after cancer diagnosis. Multiple logistic 
regression was used to identify the factors related to CAM discontinuation. Results: Among the surveyed 
cancer patients, 25.3% (674 of 2,661) had used CAM, whereas 38.3% (258 of 674) of those with CAM 
experience had discontinued CAM therapy. The most frequently used form of CAM was herbs (43.5%). 
The major reasons for the discontinuation of CAM included absence of effects (23.9%), financial burden 
(22.9%), and physician opposition (13.7%). Other factors associated with the discontinuation of CAM 
included metastatic cancer (OR = 2.06), a long duration of cancer treatment (OR = 3.34), dissatisfaction (OR 
= 4.34), and side effects (OR = 4.23) of CAM therapy. Conclusions: For cancer patients to correctly employ 
CAM therapy, increase their satisfaction, and reduce their side effects, efforts should be made to analyze the 
cost effectiveness of CAM, and valid information must be provided to physicians and cancer patients.
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Introduction
	 Despite	 the	significant	contribution	of	advances	 in	
modern	medicine	to	the	survival	rates	of	cancer	patients	
(Siegel et al., 2012), cancer remains the disease that 
instills	 the	most	 fear	 (Donovan	 et	 al.,	 2003).	 Indeed,	
the	term	‘cancer’	is	often	perceived	as	being	associated	
with	 an	 unpleasant,	 painful	 death	 	 (Donovan	 et	 al.,	
2003; Takahasi et al., 2012). Accordingly, many cancer 
patients	 use	CAM	with	 a	 hope	 that	 it	will	 assist	 in	
their	 treatment.	Defined	 by	 the	National	Center	 for	
Complementary	 and	Alternative	Medicine	 (NCCAM)	
as	“a	group	of	diverse	medical	and	health	care	systems,	
practices,	and	products	that	are	not	presently	considered	
to	be	part	of	conventional	medicine	(National	Center	for	
Complementary	and	Alternative	Medicine,	2012),”	CAM	
is	not	a	conventional	means	of	treatment.	Nonetheless,	
CAM	 is	 attracting	 a	 significant	 level	 of	 interest	 from	
cancer	 patients	 due	 to	 the	 psychological	 support	 it	
provides.	According	 to	 previous	 studies,	 the	most	
frequently	 used	 form	of	CAM	 is	 herbs	 (Samur	 et	 al.,	
2001;	Molassiotis	et	al.,	2005;	Er	et	al.,	2008;	Choi	et	
al.,	2012;	Saibul	et	al.,	2012;	Nazik	et	al.,	2012).	Cancer	
patients	are	thought	to	employ	CAM	to	increase	physical	
strength,	 restrain	cancer	growth,	enhance	 the	 immune	
system, and alleviate symptoms (Hyodo et al., 2005; 
Molassiotis	et	al.,	2005;	Molassiotis	et	al.,	2006;	Er	et	
al.,	2008;	Shin	et	al.,	2009;	Saibul	et	al.,	2012).	
	 Despite	 such	 anticipated	 gains,	 herbal	 remedies	
occasionally	 cause	 severe	 side	 effects,	 including	
high	 blood	 pressure,	 renal	 failure,	 and	 liver	 damage	
(Markman.,	 2002;	 Niggemann	 and	 Gruber,	 2003;	
Stickel	 et	 al.,	 2005).	Many	 cancer	 patients	 face	 such	
negative	 consequences	 as	 they	utilize	CAM	based	on	
the	recommendation	of	their	families	and	acquaintances	
and	 fail	 to	 consult	 their	 physicians.	Therefore,	 it	 is	
important	 to	maintain	communication	between	cancer	
patients	and	their	physicians	on	issues	related	to	CAM.	
Whereas	previous	studies	related	to	CAM	have	analyzed	
the	prevalence	of	its	use,	patient	motivation,	and	factors	
related	to	CAM	use	(Downer	et	al.,	1994;	Crocetti	et	al.,	
1998;	Boon	et	al.,	2000;	Paltiel	et	al.,	2001;	Samur	et	al.,	
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2001;	Shumay	et	al.,	2002;	Harris	et	al.,	2003;	Hyodo	
et	al.,	2005;	Molassiotis	et	al.,	2005;	Yates	et	al.,	2005;	
Molassiotis	et	al.,	2006;	Swarup	et	al.,	2006;	Montazeri	
et	al.,	2007;	Er	et	al.,	2008;	Shin	et	al.,	2009;	Choi	et	al.,	
2012;	Saibul	et	al.,	2012),	there	has	been	little	research	
on	the	issues	associated	with	discontinuation	of	CAM	by	
cancer.	Although	recent	reports	have	described	the	rates	
of	CAM	discontinuation	among	cancer	patients	(Hyodo	
et	al.,	2005;	Kim	et	al.,	2007;	Porter	et	al.,	2008),	these	
studies	have	been	limited	by	small	sample	sizes	(Kim	et	
al.,	2007;	Porter	et	al.,	2008),	a	focus	on	a	specific	cancer	
type	(Porter	et	al.,	2008),	or	a	limited	geographical	area	
(Kim et al., 2007).
	 In	 this	nationwide	multicenter	 study	 in	Korea,	we	
investigated	the	reasons	for	CAM	discontinuation	and	
identified	 the	 patient	 characteristics	 and	other	 factors	
associated	with	 the	 discontinuation	 of	CAM	 among	
cancer patients.
Materials and Methods
Study Sample and Procedures
	 We	performed	 a	 nationwide	 survey	 involving	one	
National	Cancer	Center	and	nine	regional	cancer	centers	
from	July	 to	August	2008.	This	 study	was	performed	
as	part	of	an	annual	national	survey	to	investigate	the	
experience	of	cancer	survivors.	Using	a	quota	sampling	
method,	 patients	 older	 than	18	years	 of	 age	who	had	
received	 a	 cancer	 diagnosis	 at	 least	 4	months	 earlier	
were	 recruited	 from	 one	 national	 and	 nine	 regional	
cancer	centers	in	each	of	the	nine	Korean	provinces,	so	
that	 study	 subjects	were	 as	 representative	 as	 possible	
in	 terms	of	cancer	 type,	 residence,	age,	and	sex.	This	
study	was	approved	by	the	Institutional	Review	Board	
of	the	National	Cancer	Center	in	Korea.	The	survey	was	
developed	 through	a	 literature	review	and	discussions	
with	 experts,	 and	 it	was	 tested	 in	 pilot	 surveys.	Pilot	
Table 1. Characteristics of Cancer Patients and Prevalence of CAM Discontinuation       
Characteristic	 																																																	CAM	use	 																						CAM	Discontinuation																						p
	 	 N	 (%)	 Yes	 (%)	 No	 (%)	
Sex	 Male	 314	 (46.6)	 123	 (39.2)	 191	 (60.8)	 0.66
	 Female	 360	 (53.4)	 135	 (37.5)	 225	 (65.5)	
Age	(years)	 <60	 403	 (59.8)	 151	 (37.5)	 252	 (62.5)	 0.60
	 ≥60	 271	 (40.2)	 107	 (39.5)	 164	 (60.5)	
Education		 ≤High	school		 541	 (80.8)	 204	 (37.7)	 337	 (62.3)	 0.48
	 >High	school	 129	 (19.2)	 53	 (41.1)	 76	 (58.9)	
Household	Income	 <100	million	won	 153	 (22.9)	 58	 (37.9)	 95	 (62.1)	 0.99
	 100-300	million	won	 298	 (44.5)	 113	 (37.9)	 185	 (62.1)	
	 >300	million	won	 218	 (32.6)	 82	 (37.6)	 136	 (62.4)	
Spouse	 Yes	 573	 (85.1)	 214	 (37.4)	 359	 (62.6)	 0.28
	 No		 100	 (14.9)	 43	 (43.0)	 57	 (57.0)	
Religion	 Yes	 213	 (31.6)	 78	 (36.6)	 135	 (63.4)	 0.55
	 No	 461	 (68.4)	 180	 (39.1)	 281	 (60.9)	
Cancer	sites	 Stomach	 101	 (15.0)	 30	 (29.7)	 71	 (70.3)	 0.20
	 Lung	 77	 (11.4)	 36	 (46.7)	 41	 (53.3)	
	 Liver	 70	 (10.4)	 28	 (40.0)	 42	 (60.0)	
	 Colon/rectum	 64	 (9.5)	 23	 (35.9)	 41	 (64.1)	
	 Breast	 145	 (21.5)	 50	 (34.5)	 95	 (65.5)	
	 Cervix	 31	 (4.6)	 11	 (35.5)	 20	 (64.5)	
	 Others	 186	 (27.6)	 80	 (43.0)	 106	 (57.0)	
Metastasis	 Yes	 200	 (31.4)	 100	 (50.0)	 100	 (50.0)	 <0.001
	 No	 436	 (68.6)	 143	 (32.8)	 293	 (67.2)	
Time	since	diagnosis	 ≤12	months	 203	 (30.1)	 59	 (29.1)	 144	 (70.9)	 0.004
	 12-36	month	 234	 (34.7)	 91	 (38.9)	 143	 (61.1)	
	 36-60	month	 118	 (17.5)	 51	 (43.2)	 67	 (56.8)	
	 >60	month	 119	 (17.7)	 57	 (47.9)	 62	 (52.1)	
Surgery	 Yes	 506	 (75.1)	 189	 (37.4)	 317	 (62.6)	 0.39
	 No	 168	 (24.9)	 69	 (41.1)	 99	 (58.9)	
Chemotherapy	 Yes	 450	 (66.8)	 175	 (38.9)	 275	 (37.1)	 0.64
	 No	 224	 (33.2)	 83	 (61.1)	 141	 (62.9)	
Radiotherapy	 Yes	 230	 (34.1)	 103	 (44.8)	 127	 (55.2)	 0.01
	 No	 444	 (65.9)	 155	 (34.9)	 289	 (65.1)	
CAM	use	before	diagnosis	 Yes	 122	 (18.1)	 48	 (39.3)	 74	 (60.7)	 0.79
	 No	 552	 (81.9)	 210	 (38.0)	 342	 (62.0)	
Discussed	with	doctor	 Yes	 220	 (32.6)	 77	 (35.0)	 143	 (65.0)	 0.22
	 No	 454	 (67.4)	 181	 (39.9)	 273	 (60.1)	
Satisfaction	with	CAM	use		 Satisfied		 550	 (81.6)	 177	 (32.2)	 373	 (67.8)	 <0.001
	 Dissatisfied	 124	 (18.4)	 81	 (65.3)	 43	 (34.7)	
Side	effects	of	CAM	use	 Yes	 28	 (4.2)	 22	 (78.6)	 62	 (1.4)	 <0.001
	 No	 645	 (95.8)	 236	 (36.6)	 409	 (63.4)	
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surveys	conducted	in	each	cancer	center	showed	that	the	
patients	 experienced	no	problems	with	 understanding	
the	questions,	participating	in	the	face-to-face	interview,	
or	 the	 content	 validity	 of	 the	 questionnaires.	 Patient	
information	was	 obtained	 via	 semi-structured	 face-
to-face	 interviews.	 Interviews	were	 performed	 by	
trained interviewers, who approached the patients in 
the	 outpatient	 clinics	 and	 inpatient	 departments.	 In	
total,	2,661	patients	were	surveyed,	all	of	whom	signed	
a	 consent	 form	 after	 receiving	 complete	 information	
regarding	 the	 study.	We	defined	CAM	as	any	 therapy	
that	was	not	currently	part	of	the	conventional	medical	
treatment	of	cancer	patients	and	classified	these	according	
to	NCCAM	definitions,	such	as	natural	products	(e.g.,	
herbs,	foods,	probiotics,	etc.),	mind–body	medicine	(e.g.,	
mediation,	prayer,	mental	healing,	etc.),	manipulation-	
and	body-based	practices	 (e.g.,	massage,	chiropractic,	
etc.), and whole-system medical approaches (e.g., 
traditional Chinese medicine, homeopathic medicine) 
(National	Center	 for	 complementary	 and	Alternative	
Medicine,	2012).	The	use	of	at	least	one	of	the	above	
therapies	 after	 cancer	 diagnosis	was	defined	 as	CAM	
use.	Of	the	patients	surveyed,	674	were	analyzed	as	they	
utilized	CAM	after	cancer	diagnosis.
	 The	 survey	 included	 socio-demographic	 questions	
such	as	age,	sex,	education,	household	income,	marital	
status,	 religion,	 insurance	 type,	 and	 private	 health	
insurance.	 Clinical	 questions	 addressed	 the	 cancer	
type,	stage,	duration	of	disease,	and	current	 treatment	
status.	Information	associated	with	CAM,	including	the	
types	of	CAM	used,	CAM	use	before	cancer	diagnosis,	
discussion	with	physicians,	satisfaction,	side	effects	of	
CAM,	and	the	reasons	for	discontinuation	was	obtained.	
To	determine	the	reasons	for	discontinuation	of	CAM,	
patients	who	had	ever	discontinued	CAM	were	asked	
the	survey	question,	“Why	did	you	discontinue	CAM	
use?”	The	 response	 choices	were:	 (a)	 “Experienced	
side	 effects”;	 (b)	 “Not	 as	 effective	 as	 expected”;	 (c)	
“Doctor	was	 opposed	 to	 using	CAM”;	 (d)	 “Imposed	
a	 financial	 burden”;	 (e)	 “Patient’s	 opposition”;	 (f)	
“Family’s	 opposition”;	 (g)	 “Treatment	 termination”;	
(h)	 “Aggravation	 of	 disease”;	 and	 (i)	 “Other.”	We	
additionally	gathered	the	clinical	characteristics	of	the	
patients	from	medical	records	including	the	site	of	the	
primary cancer and the stage at diagnosis. 
Statistical Analyses
	 The	chi-square	test	was	used	to	examine	differences	
in	 the	 discontinuation	 of	CAM	 according	 to	 socio-
demographic	 and	 clinical	 variables.	Additionally,	we	
performed	 a	 univariate	 analysis	 of	 factors	 predicting	
CAM	discontinuation.	Then,	we	entered	variables	found	
to	be	significantly	associated	with	CAM	discontinuation	
in	 the	 univariate	 analysis	 into	 a	multiple	 logistic	
regression	model.	The	criterion	for	variable	entry	was	P	
=	0.05.	Age,	gender,	education,	monthly	income,	marital	
status,	religion,	metastasis,	and	treatment	type	such	as	
surgery,	chemotherapy,	and	radiotherapy	were	included	
in	a	basic	predictive	model.	All	statistical	analyses	were	
two-tailed	with	a	P	<	0.05,	and	data	management	was	
performed	using	Statistical	Analysis	Software	version	
9.2.	
 
Results 
	 Among	the	2,661	cancer	patients	surveyed,	this	study	
was	conducted	with	674	(25.3%)	who	had	used	CAM.	
It	was	found	that	258	(38.3%)	of	the	674	patients	who	
used	CAM	discontinued	its	use.	The	average	age	of	the	
study	subjects	was	55.9	years.	The	most	frequently	used	
forms	of	CAM	were	herbs	(43.5%)	and	food	(32.0%).	
Comparison	 of	 CAM	 discontinuation	 according	 to	
patients’	 clinical	 characteristics	 showed	 that	 CAM	
discontinuation	 rates	were	 high	 among	 patients	who	
had	been	diagnosed	with	cancer	 for	5	years	or	 longer	
and	those	who	had	received	radiotherapy	(P	<	.05).	A	
high	rate	of	CAM	discontinuation	was	observed	among	
patients	who	expressed	dissatisfaction	with	CAM	or	had	
experienced	side	effects	(P	<	.001)	(Table	1).	
	 Regarding	 the	 reasons	 for	CAM	discontinuation,	
23.9%	of	respondents	claimed	a	lack	of	effectiveness,	
22.9%	 identified	 a	 financial	 burden,	 13.7%	 reported	
doctor	 opposition,	 and	 5.5%	 of	 the	 respondents	
discontinued	CAM	due	to	side	effects	(Table	2).
	 The	 significant	 factors	 associated	 with	 the	
discontinuation	 of	CAM	 included	metastatic	 cancer	
(OR	=	 2.03,	 95%	CI	 1.37-3.01),	 a	 long	 duration	 of	
cancer	treatment	(OR	=	2.05,	2.53,	3.28	respectively),	
dissatisfaction	with	CAM	use	(OR	=	4.33,	2.73-6.88),	and	
side	effects	from	CAM	(OR	=	4.05,	1.49-11.02)	(Table	
3).
 
Discussion
In	this	nationwide	multicenter	survey	of	2,661	cancer	
patients	in	Korea,	we	found	that	674	patients	(25.3%)	
used	CAM,	 and	 258	 (38.3%)	 of	 these	 discontinued	
CAM	use.	Previous	studies	 reported	 that	 the	majority	
of	 patients	with	CAM	experience	 initiated	CAM	use	
following	 their	 diagnosis	with	 cancer	 (Paltiel	 et	 al.,	
2001;	Hyodo	 et	 al.,	 2005;	Molassiotis	 et	 al.,	 2005;	
Yates	et	al.,	2005;	Molassiotis	et	al.,	2006;	Kim	et	al.,	
Table 2. Reason for CAM Discontinuation   
Reasons																																																																	CAM	Use	
	 N	 (%)
Side	effects	 16	 (5.5)
Not	effective	 70	 (23.9)
Doctor	opposition	 40	 (13.7)
Financial	burden	 67	 (22.9)
Patient	did	not	want	 44	 (15.0)
Family did not want 2 (0.7)
Relief	of	symptoms/Treatment	termination	 14	 (4.8)
Disease	progression	 9	 (3.1)
Others	 31	 (10.6)
Total*	 293	 (100.0)
*	Value	allowed	duplicate	responses	 	
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Table 3. Factors Associated with CAM Discontinuation     
Variables	 	 						Univariate	analysis	 					Multivariate	analysis	
	 	 OR	 			95%	CI	 OR	 95%	CI
Sex	 Male	 1.00	 	 1.00	
	 Female	 0.93	 (0.68-1.27)	 0.89	 (0.59-1.35)
Age	(years)	 <60	 1.00	 	 1.00	
	 ≥60	 1.09	 (0.79-1.49)	 1.04	 (0.69-1.58)
Household		 Low	 1.00	 	 1.00	
income	 Middle	 1.00	 (0.67-1.49)	 1.00	 (0.61-1.64)
	 High	 0.99	 (0.65-1.51)	 1.08	 (0.62-1.88)
Spouse	 Yes	 1.00	 	 1.00	
	 No	 1.27	 (0.82-1.95)	 1.16	 (0.70-1.93)
Religion	 No	 1.00	 	 1.00	
	 Yes	 1.11	 (0.79-1.55)	 1.15	 (0.78-1.70)
Metastasis	 No	 1.00	 	 1.00	
	 Yes	 2.05	 (1.46-2.89)	 2.03	 (1.37-3.01)
Time	since	diagnosis	 ≤12	months	 1.00	 	 1.00	
(month)	 12-36	month	 1.55	 (1.04-2.32)	 2.05	 (1.28-3.28)
	 36-60	month	 1.86	 (1.16-2.98)	 2.53	 (1.46-4.38)
	 >60	month	 2.24	 (1.40-3.59)	 3.28	 (1.90-5.68)
Surgery	 No	 1.00	 	 1.00	
	 Yes	 0.86	 (0.60-1.22)	 0.9	 (0.58-1.39)
Chemotherapy	 No	 1.00	 	 1.00	
	 Yes	 1.08	 (0.77-1.51)	 0.73	 (0.49-1.10)
Radiotherapy	 No	 1.00	 	 1.00	
	 Yes	 1.51	 (1.09-2.09)	 1.52	 (1.03-2.23)
CAM	use	before	diagnosis	 No	 1.00	 	 1.00	
	 Yes	 1.06	 (0.71-1.58)	 1.13	 (0.71-1.80)
Discuss	CAM	with	doctor	 No	 1.00	 	 1.00	
	 Yes	 0.81	 (0.58-1.14)	 0.89	 (0.61-1.30)
Satisfaction	with	CAM	Use	 Yes	 1.00	 	 1.00	
	 No	 3.97	 (2.63-5.99)	 4.33	 (2.73-6.88)
Side	effects	of	CAM	 No	 1.00	 	 1.00	
	 Yes	 6.36	 (2.54-15.89)	 4.05	 (1.49-11.02)
2007;	Shin	et	al.,	2009).	CAM	use	ranging	from	32	to	
67%	among	cancer	patients	has	been	reported	(Boon	et	
al.,	2000;	Paltiel	et	al.,	2001;	Samur	et	al.,	2001;	Harris	
et	al.,	2003;	Molassiotis	et	al.,	2005;	Montazeri	et	al.,	
2007;	Shin	et	al.,	2009).	One	study	indicated	that	91%	
of	cancer	patients	use	one	or	more	forms	of	CAM	(Yates	
et	al.,	2005).	Similar	to	the	initiation	rates	of	CAM	use,	
CAM	discontinuation	rates	were	reported	to	range	widely	
from	26	to	63%	(Hyodo	et	al.,	2005;	Kim	et	al.,	2007).	
Consistent	with	previous	studies	on	CAM	use	(Harris	
et	 al.,	 2003;	Hyodo	 et	 al.,	 2005;	Chung	 et	 al.,	 2006;	
National	Center	 for	Complementary	 and	Alternative	
Medicine,	2012),	our	results	suggest	that	cancer	patients	
experience	high	levels	of	satisfaction	and	relatively	few	
side	effects	following	CAM	use.	However,	32.2%	of	the	
cancer	patients	who	were	satisfied	with	CAM	and	36.6%	
of	those	who	did	not	experience	side	effects	nevertheless	
discontinued	CAM	use.	These	figures	suggest	that	despite	
the	 satisfactory	 experiences	with	CAM,	CAM	users	
frequently	question	its	use	due	to	its	financial	burden	and	
unverified	effectiveness.	Additionally,	considering	that	
CAM	discontinuation	rates	increased	with	the	duration	
of	cancer	treatment,	further	studies	should	be	conducted	
to	explain	the	costs	of	CAM	and	its	cost-effectiveness.	
Previous	studies	reported	that	the	majority	of	cancer	
patients	 obtain	 information	 concerning	CAM	 from	
families	and	friends	(Samur	et	al.,	2001;	Hyodo	et	al.,	
2005;	Chung	et	al.,	2006;	Molassiotis	et	al.,	2006;	Er	
et	al.,	2008;	Shin	et	al.,	2009;	Choi	et	al.,	2012;	Saibul	
et	al.,	2012).	One	such	study	surveyed	the	quality	and	
reliability	of	internet	sites	related	to	CAM	(Molassiotis	
and	Xu,	2004;	Schmidt	and	Ernst,	2004)	and	found	that	
the	majority	of	sites	offered	low-quality	and	inaccurate	
information	 that	 excessively	 focuses	 on	 positive	
aspects	 of	CAM.	 It	 is	 therefore	 necessary	 to	monitor	
the	effectiveness	of	CAM	on	a	regular	basis	and	present	
accurate	information	to	physicians	and	cancer	patients.	
Some	 studies	 suggest	 that	 the	 doctors’	 negative	
opinions	regarding	CAM	may	undermine	communication	
between	cancer	patients	and	their	physicians	(Tasaki	et	
al.,	 2002)	Accordingly,	 it	 has	 been	 reported	 that	 only	
20–57%	of	cancer	patients	consult	their	doctors	regarding	
CAM	use	(Boon	et	al.,	2000;	Hyodo	et	al.,	2005;	Yates	et	
al.,	2005;	Chung	et	al.,	2006;	Er	et	al.,	2008;	Shin	et	al.,	
2009;	Choi	et	al.,	2012).	Similar	results	were	observed	in	
the	present	study,	which	found	that	only	33.8%	of	CAM	
users	 consulted	 their	 physicians,	 and	 40.7%	of	 those	
who	had	not	sought	a	doctor’s	consultation	discontinued	
CAM,	 indicating	 the	 importance	 of	 communication	
between	cancer	patients	and	their	physicians	on	issues	
related	to	CAM.	In	the	multivariate	analysis,	statistically	
significant	 factors	 associated	with	 the	discontinuation	
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of	CAM	included	cancer	progression	stage,	duration	of	
cancer	treatment,	satisfaction	regarding	CAM	use,	and	
side	effects	 from	CAM.	Compared	with	patients	with	
regional or local disease, patients with advanced disease 
were	more	likely	to	discontinue	CAM	use.	Advanced-
stage	 cancer	 patients	may	have	 a	 short	 survival	 time	
and	may	therefore	discontinue	CAM	more	easily	than	
those with regional or local disease. Considering that 
the	reasons	for	discontinuation	of	CAM	include	longer	
disease	 duration,	 being	 less	 satisfied	with	CAM,	 and	
having	CAM-induced	 side	 effects,	 it	 is	 important	 for	
doctors	 to	 verify	 the	 benefits	 of	 the	 various	 forms	of	
CAM	and	to	advise	cancer	patients	accordingly	so	that	
they	can	choose	effective	measures.	
Our	 study	has	 several	 limitations.	First,	 the	cross-
sectional	nature	of	our	study	precluded	the	determination	
of	a	causal	relationship	between	CAM	discontinuation	
and	associated	factors.	Second,	the	sample	included	only	
cancer	patients	being	 treated	at	 ten	major	hospitals	 in	
Korea	and	selected	using	quota	sampling,	and	the	study	
thus	does	not	 represent	 the	overall	cancer	population.	
However,	with	 respect	 to	 cancer	 types,	we	 obtained	
a	 similar	 distribution	 to	 the	 general	Korean	 cancer	
population	using	quota	sampling.	Also,	our	sex	and	age	
group	distributions	were	not	biased.	Therefore,	we	assert	
that	these	limitations	do	not	pose	serious	impediments	to	
the	internal	validity	or	patient	representation	of	the	study.	
Despite	the	above-mentioned	limitations,	this	study	
is	one	of	the	few	studies	to	explore	CAM	discontinuation	
issues	in	cancer	survivors.	The	results	show	that	many	
cancer	patients	decide	 to	discontinue	CAM	due	 to	 its	
lack	 of	 effectiveness;	 other	major	 factors	 associated	
with	the	discontinuation	of	CAM	include	the	duration	
of	cancer	treatment,	the	level	of	satisfaction	with	CAM	
use,	and	CAM-induced	side	effects.	Therefore,	efforts	
should	 be	made	 to	 analyze	 the	 cost-effectiveness	 of	
CAM,	and	clinical	studies	should	be	conducted	on	the	
various	forms	of	CAM	to	provide	accurate	assessment	
of	 their	 effectiveness.	 Furthermore,	 valid	 information	
must	 be	 provided	 to	 cancer	 patients	 based	 on	 active	
communication	with	physicians.	In	turn,	cancer	patients	
must	be	able	to	safely	select	appropriate	forms	of	CAM	
to	maximize	its	benefits.	
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